Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
Division of Hepatobiliary and Pancreatic Surgery, Henan Key Laboratory of Digestive Organ Transplanation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
PLoS One. 2024 Apr 17;19(4):e0299920. doi: 10.1371/journal.pone.0299920. eCollection 2024.
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths. However, the HCC treatment is still challenging. Herein, we aimed to reveal the anti-tumor effect of Jolkinolide B in HCC cell lines Huh-7 and SK-Hep-1. The results showed that Jolkinolide B inhibited the migration, invasion, and epithelial-to-mesenchymal transition(EMT) of HCC cells. In addition, Jolkinolide B induced HCC cell apoptosis by upregulating Bax and downregulating BCL-2 expressions. Furthermore, we demonstrated that Jolkinolide B inactivated the β-catenin signaling and reduced Musashi-2 expression. Finally, we revealed that Musashi-2 overexpression reversed the Jolkinolide B-induced anti-HCC effect. Overall, we proved that Jolkinolide B is a potential candidate for treating HCC.
肝细胞癌（HCC）是癌症相关死亡的主要原因之一。然而，HCC 的治疗仍然具有挑战性。在此，我们旨在揭示冬凌草甲素 B 在 HCC 细胞系 Huh-7 和 SK-Hep-1 中的抗肿瘤作用。结果表明，冬凌草甲素 B 抑制 HCC 细胞的迁移、侵袭和上皮间质转化（EMT）。此外，冬凌草甲素 B 通过上调 Bax 和下调 BCL-2 的表达诱导 HCC 细胞凋亡。此外，我们证明冬凌草甲素 B 使 β-catenin 信号失活并降低 Musashi-2 的表达。最后，我们揭示了 Musashi-2 的过表达逆转了冬凌草甲素 B 诱导的抗 HCC 作用。总的来说，我们证明了冬凌草甲素 B 是治疗 HCC 的潜在候选药物。
